Identification of Laboratory Biomarkers for Early Detection and Clinical Management of Post-Acute Syndrome Among Survivors of the 2013-2016 West Africa Ebola Outbreak in Sierra Leone.

Ebola virus disease biochemical biomarkers hematological immunological post-acute syndrome

Journal

Journal of blood medicine
ISSN: 1179-2736
Titre abrégé: J Blood Med
Pays: New Zealand
ID NLM: 101550884

Informations de publication

Date de publication:
2023
Historique:
received: 18 04 2022
accepted: 07 02 2023
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 24 2 2023
Statut: epublish

Résumé

The clinical management of persistent medical conditions affecting Ebola survivors, generally described as a post-Ebola syndrome, remains a public health concern. We aimed to analyze Ebola survivors' laboratory biomarkers as compared to their non-infected household relatives to identify biomarkers that could guide the identification of survivors at increased risk of developing severe at odds with the non-severe post-Ebola syndrome. Data were extracted from medical records of the Ebola survivors clinic, and we included only Ebola survivor's parameters recorded during the first baseline follow-up visit 2 weeks interval after their second negative PCR result. Moreover, household non-infected family contacts of survivors visiting the clinic during the same period were recruited as community control. The mean age of survivors was 32.65 (IQR: 15.5, 38.25) years, and Ebola IgG immunoglobulin was detected in all, thus confirming their status. The statistical significance (all p < 0.05) observed in monocyte percentage (MONO%), cluster of differentiation 4 percentage (CD4%), alanine aminotransferase (ALT), creatinine (CREA), and creatinine kinase (C-kinase) proved to be clinically significant as compared to the household relatives' group. Interestingly, the linear regression analysis indicated that the duration at ETU was negatively associated with lymphocyte percentage with a 5% lymphocyte decrease per day spent at ETU. Finally, there was a significant (p < 0.05) association between hematological (Hb, PCV, MCV, MCH), biochemical (ALT, CREA, C-kinase, T-cholesterol, triglycerides) parameters and the risk of developing severe complications. We recommend clinicians closely monitor Hb, PCV, MCV, MCH, ALT, CREA, C-kinase, T-cholesterol, triglycerides and lymphocytes as clinically relevant laboratory biomarkers to identify survivors at higher risk of developing severe post-acute syndrome upon discharge from Ebola treatment unit including headache, abdominal pain, chest pain, ocular complication, arthralgia, hearing difficulty and erectile dysfunction which can impact health-related quality of life among Ebola survivors.

Sections du résumé

Background UNASSIGNED
The clinical management of persistent medical conditions affecting Ebola survivors, generally described as a post-Ebola syndrome, remains a public health concern. We aimed to analyze Ebola survivors' laboratory biomarkers as compared to their non-infected household relatives to identify biomarkers that could guide the identification of survivors at increased risk of developing severe at odds with the non-severe post-Ebola syndrome.
Materials and Methods UNASSIGNED
Data were extracted from medical records of the Ebola survivors clinic, and we included only Ebola survivor's parameters recorded during the first baseline follow-up visit 2 weeks interval after their second negative PCR result. Moreover, household non-infected family contacts of survivors visiting the clinic during the same period were recruited as community control.
Results UNASSIGNED
The mean age of survivors was 32.65 (IQR: 15.5, 38.25) years, and Ebola IgG immunoglobulin was detected in all, thus confirming their status. The statistical significance (all p < 0.05) observed in monocyte percentage (MONO%), cluster of differentiation 4 percentage (CD4%), alanine aminotransferase (ALT), creatinine (CREA), and creatinine kinase (C-kinase) proved to be clinically significant as compared to the household relatives' group. Interestingly, the linear regression analysis indicated that the duration at ETU was negatively associated with lymphocyte percentage with a 5% lymphocyte decrease per day spent at ETU. Finally, there was a significant (p < 0.05) association between hematological (Hb, PCV, MCV, MCH), biochemical (ALT, CREA, C-kinase, T-cholesterol, triglycerides) parameters and the risk of developing severe complications.
Conclusion UNASSIGNED
We recommend clinicians closely monitor Hb, PCV, MCV, MCH, ALT, CREA, C-kinase, T-cholesterol, triglycerides and lymphocytes as clinically relevant laboratory biomarkers to identify survivors at higher risk of developing severe post-acute syndrome upon discharge from Ebola treatment unit including headache, abdominal pain, chest pain, ocular complication, arthralgia, hearing difficulty and erectile dysfunction which can impact health-related quality of life among Ebola survivors.

Identifiants

pubmed: 36817368
doi: 10.2147/JBM.S371239
pii: 371239
pmc: PMC9930681
doi:

Types de publication

Journal Article

Langues

eng

Pagination

119-132

Informations de copyright

© 2023 Guetiya Wadoum et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Clin Infect Dis. 2016 Jun 1;62(11):1360-1366
pubmed: 27001797
Lancet Infect Dis. 2015 Nov;15(11):1292-9
pubmed: 26271406
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2193-2200
pubmed: 28695354
Viruses. 2012 Sep;4(9):1668-86
pubmed: 23170178
Emerg Infect Dis. 2016 Apr;22(4):641-6
pubmed: 26983037
Open Forum Infect Dis. 2016 Feb 22;3(1):ofw031
pubmed: 27004234
Lancet Infect Dis. 2015 Aug;15(8):905-12
pubmed: 25910637

Auteurs

Raoul Emeric Guetiya Wadoum (RE)

Department of Public Health, Microbiology and Immunology, Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.

Stephen Sevalie (S)

34th Military Hospital, The Republic of Sierra Leone Armed Forces, Freetown, Sierra Leone.

Maurice Baimba Kargbo (M)

Department of Agriculture and Food Security; Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.

Andrew Clarke (A)

Global Programs Division, Save the Children UK, London, UK.
Department/Division of Health Research, Lancaster University, Lancaster, UK.

Sherry Bangura (S)

Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.

Mariatu Kargbo (M)

Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.

Hawa Mariama Sesay (HM)

Department of Public Health, University of Makeni, Makeni, Sierra Leone.

Abdul H Kamara (AH)

Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.

Jamil Bangura (J)

Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.

Alie F Kamara (AF)

Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone.

Sophie Allieu (S)

Department of Public Health, Microbiology and Immunology, Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.

Hassan Rogers (H)

Department of Public Health, Microbiology and Immunology, Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.

Maurizio Mattei (M)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Vittorio Colizzi (V)

Department of Sciences and Technology, Evangelical University of Cameroon, Bandjoun, Cameroon.

Carla Montesano (C)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Edwin J J Momoh (EJJ)

Department of Public Health, Microbiology and Immunology, Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.
Department of Agriculture and Food Security; Ernest Bai Koroma University of Science and Technology, Makeni, Sierra Leone.

Classifications MeSH